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Abstract 
Achalasia is a primary motor disorder of the eso­
phagus, in which esophageal emptying is impaired. 
Diagnosis of achalasia is based on clinical findings. The 
diagnosis is confirmed by radiographic, endoscopic, 
and manometric evaluations. Several treatments for 
achalasia have been introduced. We searched the 
PubMed Database for original articles and meta­
analyses about achalasia to summarize the current 
knowledge regarding this disease, with particular focus 
on different procedures that are used for treatment 
of achalasia. We also report the Iranian experience of 
treatment of this disease, since it could be considered 
as a model for medium­resource countries. Myotomy, 
particularly laparoscopic myotomy with fundoplication, 
is the most effect ive treatment for achalas ia. 
Compared to other treatments, however, the initial cost 
of myotomy is usually higher and the recovery period 
is longer. When performing myotomy is not indicated 
or not possible, graded pneumatic dilation with slow 
rate of balloon inflation seems to be an effective and 
safe initial alternative. Injection of botulinum toxin 
into the lower esophageal sphincter before pneumatic 
dilation may increase remission rates. However, this 
needs to be confirmed in further studies. Due to lack of 
adequate information regarding the role of expandable 
stents in the treatment of achalasia, insertion of 
stents does not currently seem to be a recommended 
treatment. In summary, laparoscopic myotomy can be 
considered as the procedure of choice for treatment 
of achalasia. Graded pneumatic dilation is an effective 
alternative when the performance of myotomy is not 
possible for any reason. 
INTRODUCTION
 
Achalasia is the most recognized primary motor disorder 
of the esophagus. In idiopathic achalasia, inhibitory 
ganglion cells in the myenteric plexuses of the esophagus 
undergo inflammatory degeneration. The term achalasia 
means “failure to relax”; the loss of ganglion cells 
leads to a defect in lower esophageal sphincter (LES) 
relaxation, which is the principal feature of idiopathic 
achalasia and causes functional obstruction of the 
esophagus, and reduced peristalsis in the esophageal 
body, which further impairs esophageal emptying. The 
functional obstruction in the LES is overcome only 
when the hydrostatic pressure of the retained material 
in the esophagus exceeds the LES pressure[1]. Secondary 
achalasia may occur following several conditions, which 
are listed in Table 1. 
The reported annual incidence of achalasia is 
approximately 1 per 100 000[2]. Men and women are 
affected with equal frequency[3]. Although achalasia is 
diagnosed mainly in people aged between 25 and 60 
years, it may occur at any age[2-4]. In general, achalasia 
has a subtle onset, and symptoms progress gradually. 
Therefore, patients experience symptoms for months 
or years before their disease is diagnosed. In a series of 
87 patients with newly-diagnosed achalasia, the mean 
duration of symptoms was 4.7 years. The delay in 
diagnosis was due to misinterpretation of symptoms by 
physicians and atypical clinical manifestations[5]. Many 
patients are treated for other disorders such as gastro-
esophageal reflux disease (GERD) before the diagnosis 
of achalasia is made[3]. The main symptom of achalasia 
is dysphagia[3]. To relieve dysphagia and other symptoms 
of achalasia, several treatments have been introduced, 
www.wjgnet.com 
  
 
 
  
 
  
 
        
        
     
        
         
         
         
         
      
      
 
 
 
 
 
 
  
        
          
         
        
         
      
     
 
 
        
         
          
         
       
        
          
          
         
          
           
         
           
        
      
  
 
 
 
 
 
 
  
                                 
including medical therapy, myotomy, pneumatic dilation 
of the LES, and injection of botulinum toxin into the 
LES. Early treatment of achalasia may also reduce the 
reported increased risk of esophageal cancer among 
patients with achalasia[6,7]. 
In this article, we report results of our review of 
medical literature on the subject of achalasia. Our aim 
is to summarize the current knowledge as regards this 
disease, with particular focus on different procedures 
that are used for treatment. Furthermore, several articles 
about achalasia have been published from Iran, mainly 
from the Digestive Diseases Research Center, Shariati 
Hospital of Tehran University of Medical Sciences, a 
nationwide referral center for the disease, where we 
provide follow-up care for 675 patients with achalasia. 
We present results of the Iranian studies, since our 
experience could be considered as a model for medium-
resource countries. 
PATHOPHYSIOLOGY
 
In achalasia, inhibitory ganglion cells in the myenteric
plexuses of the esophagus, which produce nitric oxide,
undergo inflammatory degeneration[8-10]. The remaining
ganglion cells are often surrounded by lymphocytes and,
to a lesser extent, by eosinophils[8,11]. Loss of inhibitory
ganglion cells has two consequences: (i) basal LES pressure
rises, which impairs normal relaxation of the sphincter and
esophageal emptying, and (ii) the smooth muscle layer in
the esophageal body loses normal peristalsis.
Several studies have suggested that a viral infection 
or some other environmental factor may initiate 
inflammation in the myenteric plexus. For example, a 
recent study suggested that the inflammatory reaction 
might be triggered by human herpes virus type 1[12]. 
In certain individuals, the inflammation may lead to an 
autoimmune response against ganglion cells. Genetic 
susceptibility may play a role in this process[13]. There are 
some reports of an association between some human 
leukocyte antigens and the presence of circulating 
antibodies to enteric neurons and the loss of ganglion 
cells[14]. An hereditary association between achalasia and 
some other conditions such as adrenal glucocorticoid 
deficiency and alacrima has been reported[15]. In our 
study on 25 children with achalasia, 2 cases (8%) had 
Achalasia, Alacrima, and Adrenal insufficiency (triple A 
syndrome or Allgrove syndrome) and 3 cases (12%) had 
Achalasia and Alacrima (double A syndrome). All of the 
5 cases were siblings from two families[16]. 
CLINICAL FEATURES
 
The prevalence of the main symptoms of achalasia
is shown in Table 2. The most common symptom of 
achalasia is dysphagia to solid foods (over 99%), followed
by dysphagia to liquids (90% to 95%)[17]. Although
dysphagia to liquids can occur in patients with other
esophageal motility disorders (e.g. progressive systemic
sclerosis), this symptom strongly suggests achalasia[3]. 
Regurgitation, active or passive, occurs in 70% to 
       
Table 1 Causes of secondary achalasia 
Malignancy, especially carcinoma 
Chagas’ disease 
Amyloidosis 
Sarcoidosis 
Neurofibromatosis 
Eosinophilic gastroenteritis 
Multiple Endocrine Neoplasia, type 2B 
Juvenile Sjögren’s syndrome with achalasia and gastric hypersecretion 
Chronic idiopathic intestinal pseudo-obstruction 
Anderson-Fabry disease 
                5001 Mikaeli J et al . Achalasia
Table 2 Prevalence of symptoms in achalasia 
Symptom Percentage (%) 
Dysphagia to solids 99 
Dysphagia to liquids 93 
Active regurgitation 84 
Passive regurgitation 68 
Weight loss 61 
Chest pain 59 
Nocturnal cough 45 
Heartburn 35 
Nocturnal dyspnea 20 
Hiccup  8 
80% of cases. Regurgitation can be troublesome; this 
may lead to aspiration when patients lie down[2,3]. Weight 
loss, chest pain, and heartburn occur in approximately 
40% to 60% of patients. Although severe weight loss 
can happen, the usual weight loss is 5 to 10 kg. 
Occasionally, chest pain is the presenting symptom of 
achalasia. This is more common in younger patients, and
tends to diminish with advancing age[17]. In our study of 
213 achalasia patients, chest pain was the only symptom
whose prevalence between the sexes was significantly
different, being more common among women than men
(70.9% vs 54.5%, P = 0.03, respectively)[18]. In both sexes,
chest pain did not relate to the duration of symptom
and the LES pressure. Chest pain was less frequently
reported by patients over 56 years of age compared to
those younger than 56 years (P < 0.05)[18]. It seems that
chest pain is a distinctive symptom of achalasia which
is affected by sex as well as age. Although chest pain
was not improved following pneumatic dilation in some
studies[17], others reported significant improvement after
the procedure[18].
Heartburn occurs frequently in achalasia. Patients 
with heartburn have lower LES pressures than those 
without this symptom[19]. Heartburn may occur as a 
result of gastro-esophageal reflux or other causes, such 
as direct irritation of the esophageal mucosa by foods, 
pills, and the lactate produced by bacterial fermentation 
of retained carbohydrates[19,20]. Hiccup is also a frequent 
symptom in achalasia, partly because of the obstruction 
of the distal esophagus[21]. Functional and structural 
abnormalities of the lung, such as tracheo-bronchial 
compression and abnormalities on high-resolution CT-
scan, may occur in half of the patients[22]. The frequency 
www.wjgnet.com 
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Table 3 Frequency of cardinal symptoms in achalasia 
Symptom Frequency (%) 
Each meal Daily Weekly None 
Dysphagia to solids 84 13  2  1 
Dysphagia to liquids 60 25  8  7 
Active regurgitation 33 36 15 16 
Daily Weekly Monthly None 
Passive regurgitation 20 44 4 32 
Chest pain 12 39 8 41 
of  cardinal symptoms in achalasia is shown in Table 3. 
Since patients with achalasia may experience retro-
sternal fullness following a meal, they may eat more
slowly and induce regurgitation to relieve the feeling. They
may perform some maneuvers to augment esophageal
emptying, such as lifting the neck or throwing the
shoulders back[3].
Compared to the general population, patients with 
achalasia are at substantially increased risk, even as high 
as 33-fold, of developing esophageal cancer. The cancer 
typically is of squamous cell type[6,7]. However, some 
series did not find any increase in the risk, particularly 
with early treatment of achalasia. We followed up 365 
patients with achalasia for a mean duration of 43 mo; no 
case of esophageal cancer was identified. This may be 
related to the fact that our study participants were fairly 
young (mean age, 38 years) and the duration of follow-
up was not very long[23]. 
DIAGNOSIS
 
Diagnosis of achalasia is based on clinical findings. The 
diagnosis is confirmed by radiographic, endoscopic, and 
manometric evaluations. 
Radiography 
The usual findings on a plain chest X-ray are widening 
of the mediastinum, due to esophageal dilation, and 
absence of the normal gastric air. When achalasia is 
suspected, barium swallow is the primary screening test. 
Barium swallow typically shows a dilated esophagus 
that terminates in a beak-like narrowing as a result of 
contraction in the LES. When dilation is very severe, 
the esophagus may have a sigmoid shape[3]. The overall 
sensitivity of barium swallow for diagnosis of achalasia 
is approximately 95%[24], but in early stages of the 
disease it may be reported as normal. For example, in 
a prospective study achalasia was suggested by barium 
examination in only 21 out of 33 patients who eventually 
were diagnosed with achalasia[2]. 
The timed barium esophagogram, which assesses
esophageal emptying at 1, 3 and 5 min after swallowing of 
barium, can be more helpful than usual barium swallow.
Vaezi et al[25] reported that assessing both symptom
improvement and objective improvement in esophageal
emptying can better identify the response rate to
pneumatic dilation and need for repeated dilations in the
future. In their study of 37 patients, there was a significant
association (P < 0.001) between improvement in patient
symptoms and barium height. In 38 out of 53 (72%)
pneumatic dilations, the degree of symptom and barium
height improvement was comparable. In 8 out of 26 (31%)
patients, however, there was < 50% improvement in
barium height despite near complete symptom resolution.
Age was the only difference between the groups and
patients with improvement in both symptoms and
barium height, i.e. the first group, were significantly older
than the second. They concluded that the timed barium
esophagogram before and after dilation may identify a
subset of patients with poor esophageal emptying but
with good improvement in symptoms who may benefit
from early repeated pneumatic dilation[25]. Similarly,
Chuah et al[26] found in their study of 32 patients with
achalasia who received pneumatic dilation that the timed
barium esophagograms correlated with symptomatic
improvement in up to 71% of patients, although seven
patients who noted complete symptom resolution showed
less than 50% improvement in barium column height
and esophageal diameter. In a study of 52 patients, we
also found that the volume of barium retention at 5 min
could predict the LES pressure before and after balloon
dilation in achalasia[27], and in a study of 43 patients,
surface area of barium retention at 5 min appeared to be
an even better predictor for resting LES pressure[28]. In a
randomized clinical trial of 51 patients who underwent
surgery or pneumatic dilation, results of the timed barium
esophagogram also correlated well with outcome. Poor
improvement in barium height following the treatments
was associated with an increased risk of treatment
failure[29].
Manometry 
Manometry is the most sensitive tool for diagnosis of 
achalasia. Elevated resting LES pressure (usually >
45 mmHg), incomplete LES relaxation, and aperistalsis 
in the smooth muscle portion of the body of the 
esophagus are three characteristic manometric features 
of achalasia[30]. Swallows may be followed by either no 
esophageal contraction or simultaneous contractions. 
Simultaneous contractions may also occur spontaneously. 
Another common feature is that resting pressure in the 
body of the esophagus is slightly higher than in the 
stomach[3]. 
In most patients the amplitude of esophageal 
contractions is low. On the other hand, in vigorous 
achalasia the simultaneous esophageal contractions have 
high amplitudes (e.g. > 60 mmHg). Some studies have 
suggested that vigorous achalasia may represent an early 
form of achalasia in which some inhibitory ganglion 
cells may not yet be destroyed[8], and that patients with 
vigorous achalasia may benefit more from botulinum 
toxin injection than those with classic achalasia[31]. At 
present, however, the distinction between vigorous and 
classic achalasia seems to have little clinical significance. 
Endoscopy 
Endoscopy in achalasia typically reveals a dilated
www.wjgnet.com 
       
      
       
        
            
           
       
         
       
      
      
        
      
        
      
         
        
 
        
         
       
    
 
 
 
       
 
 
 
      
 
 
   
        
          
          
        
       
         
           
        
           
        
        
esophagus that often contains retained material. The
esophageal mucosa usually appears normal, although
inflammation and ulceration may result from chronic
inflammation caused by retained food or pills. Endoscopy
may be reported as normal if it is carried out in the
early stages of the disease or it is not performed by
experienced endoscopists[2]. Achalasia at early stages may
also be misdiagnosed as GERD. Food stasis and GERD
are main factors contributing to esophageal mucosal
inflammation in achalasia. The association between
endoscopic food stasis and histological inflammation
is significant, but endoscopic signs of esophagitis and
histological inflammation are poorly associated. Because
of low sensitivity of endoscopy to detect inflammation,
surveillance endoscopy with biopsy sampling and
assessment of stasis is warranted to detect early neoplastic
changes[32]. The stasis may predispose the esophagus to
Candida infection. 
Although the LES in achalasia is contracted, the
endoscope can usually be traversed easily into the stomach
aided by gentle pressure on the scope[3].
Endoscopic ultrasonography (EUS) may show 
widening of the mean longitudinal and circular smooth 
muscle layers of the LES; however, this finding is not 
specific for achalasia[33]. We compared the esophageal 
muscularis propria thickness in achalasia patients with a 
control group using EUS and assessed the relationship 
between EUS findings and demographic features in both 
groups. The esophageal muscular layer was significantly 
thicker in patients with achalasia compared to control 
group (P < 0.05). Among patients with achalasia, the 
thickness at 5 and 10 cm above the gastro-esophageal 
junction appeared to be correlated with age, being higher 
among older people[34]. 
Clinical and endoscopic features of some other 
conditions, such as neoplasms, may be similar to those 
of achalasia. Since gastric adenocarcinoma is the most 
common neoplasm associated with pseudo-achalasia, the 
esophago-gastric junction and the gastric fundus should 
be carefully examined for any evidence of neoplasm. 
With certain features, malignancy is more likely: 
duration of symptoms less than 6 mo; presentation 
after the age of 60 years; excessive weight loss in spite 
of short duration of symptoms; difficult passage of the 
endoscope through the gastro-esophageal junction[35]. 
In these cases, repeated evaluations and biopsies are 
recommended. 
Symptomatic scoring 
Several scoring system have been proposed to evaluate
the severity of the symptoms in achalasia. One of the
scoring systems is shown in Table 4. In this scoring
system, scores for the following five symptoms; dysphagia
to solids, dysphagia to liquids, passive regurgitation,
active regurgitation, and chest pain are summed up to
calculate the total score. In a study of 116 patients with
achalasia, we found a good correlation between this
score and LES pressure (r = 0.29, P < 0.01)[36]. Among
the main symptoms, active and passive regurgitation and
dysphagia to liquids were significantly correlated to the
         
Table 4 Scoring system for evaluation of clinical symptoms 
Symptom Score by frequency of symptoms 
Each meal Daily Weekly None 
Dysphagia to solids 3 2 1 0 
Dysphagia to liquids 3 2 1 0 
Active regurgitation 3 2 1 0 
Daily Weekly Monthly None 
Passive regurgitation 3 2 1 0 
Chest pain 3 2 1 0 
LES relaxation pressure (P = 0.001, 0.002, and 0.046,
respectively)[36]. 
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TREATMENT
 
The mainstay of therapy is to reduce LES pressure in
order to improve esophageal emptying by gravity. Several
therapeutic modalities have been introduced to achieve
this goal, including medical therapy, surgical myotomy
(open or laparoscopic), pneumatic dilation of the LES,
injection of botulinum toxin into the LES, and insertion
of self-expanding stents. There are 3 recent meta-
analyses of publications which have investigated different
treatment approaches. One of these included 105 articles
involving 7855 subjects, and investigated symptom relief,
prevalence of gastro-esophageal reflux, and complications
following treatments[37]. Pneumatic dilation was more
successful in symptom relief than botulinum toxin
injection (68% vs 41%, P = 0.02, respectively). Symptom
relief with laparoscopic myotomy plus an anti-reflux
procedure was better (90%) than with all other treatments.
Furthermore, complication rate was low with this method
(6.3%)[37]. Likewise, another meta-analysis of randomized
and controlled treatment trials, which included 17 articles
with 761 participants and investigated remission and
relapse rates and complications, found a better remission
rate and lower relapse rate for laparoscopic myotomy
compared to other treatments. There was no difference
between open and laparoscopic myotomy, in the only trial
that compared these two methods, regarding remission
and relapse rates. Remission rate following pneumatic
dilation was higher than after botulinum toxin injection[38].
A meta-analysis of controlled and uncontrolled studies in
the Chinese literature (43 articles with 1791 participants)
also showed that myotomy was associated with higher
initial and long-term remission rates than pneumatic
dilation or botulinum toxin injection. Only 2 studies
compared open myotomy with laparoscopic myotomy;
there was no difference in remission rate[39]. Since results
after any treatment may deteriorate over time, life-long
follow-up and objective assessment of the results are
recommended.
Medical therapy 
Nitrates and calcium channel blockers (e.g. nifedipine) 
relax the smooth muscles of the LES[40]. These 
medications are usually taken sublingually 10 to 30 min 
before meals. Pharmacotherapy for achalasia, however, 
is often ineffective and frequently associated with side 
www.wjgnet.com 
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effects (e.g. headache, hypotension, and tachyphylaxis). 
Therefore, nitrates and calcium channel blockers are 
primarily used for patients who are unwilling to undergo 
or unable to tolerate more effective, invasive forms of 
therapy[3]. 
Surgical myotomy 
Surgical myotomy was first introduced by Ernst Heller
in 1913. Nowadays, a modified technique is commonly
used[41]. The standard “open” myotomy can be performed
using either an abdominal or, more commonly, a
thoracic approach[42,43]. More recently, laparoscopic and
thoracoscopic techniques have been used to perform
myotomy[39,44-46]. 
The modified Heller approach results in good to
excellent relief of symptoms in 70% to 90% of patients
with few serious complications. The mortality rate
(approximately 0.3%) is similar to that reported for
pneumatic dilation[42]. The major disadvantages of surgery
are the high initial cost, long recovery period, and the
frequent development of GERD. Reflux esophagitis
develops in approximately 10% of patients treated by
surgical myotomy[42]; however, the efficacy of proton pump
inhibitor treatment minimizes its clinical significance.
There is a debate with regard to the need for additional
fundoplication in open myotomy. In some studies, gastro-
esophageal reflux was relatively frequent even after
combining myotomy with anti-reflux procedures[47,48].
There is increasing experience with Heller myotomy
performed by minimally invasive techniques (laparoscopy
or thoracoscopy), and these techniques have become
the procedure of choice by many experienced surgeons
for uncomplicated cases in Western countries. These
approaches in several trials were more successful in
symptom relief than other treatments[37]. They are
associated with few major complications[49] and shorten the
duration of hospitalization and recovery[44,45]. Some pre-
and postoperative findings may be helpful in predicting
the outcome. In a study of 407 patients who underwent
laparoscopic myotomy, high preoperative LES pressure
(> 30 mmHg) was a predictor of a good response, while
severe chest pain and the presence of a decompensated
sigmoid esophagus (class Ⅳ) was associated with poor
outcome[50]. In a study of 200 patients who underwent
laparoscopic or thoracoscopic myotomy plus a partial
fundoplication, low LES pressure, presence of sigmoid
esophagus, and longer duration of symptoms were
associated with failure of treatment in long-term follow-
up[51]. Preoperative LES pressure over 35 mmHg was also
a strong predictor of excellent postoperative relief in
dysphagia in another study of 200 patients[52]. 
Objective analyses have shown a high rate of gastro-
esophageal reflux in laparoscopic myotomy without 
an anti-reflux procedure. In a study of 50 patients 
with achalasia who underwent laparoscopic Heller 
myotomy without anti-reflux procedures, significant 
heartburn was reported in 30% of cases. Twenty four-
hour pH monitoring revealed abnormal findings in 
11 out of 22 patients tested[53]. However, use of a 
fundoplication procedure with laparoscopic myotomy 
reduced the rate of gastro-esophageal reflux (8.8% with 
a fundoplication vs 31.5% without a fundoplication,
P = 0.003)[37]. In a study of 20 patients who underwent 
laparoscopic myotomy and fundoplication, 24-h 
combined multichannel intra-luminal impedance and pH 
monitoring did not show any evidence of postoperative 
pathologic ref lux in both upright and recumbent 
positions[54]. Few randomized trials have investigated 
the efficacy of different fundoplication techniques used 
with laparoscopic myotomy in treatment of achalasia. 
In a randomized, controlled study of 144 patients who 
underwent laparoscopic myotomy, the outcome when 
using Dor versus Nissen fundoplication was investigated. 
Both techniques were successful in long-term control 
of gastro-esophageal reflux, but the recurrence rate of 
dysphagia was higher with the Nissen method[55]. Based 
on the published literature, Dor fundoplication seems 
to be performed more commonly as the anti-reflux 
procedure during laparoscopic myotomy than other 
fundoplication techniques. 
Pneumatic dilation 
Although some studies reported similar short- and long-
term efficacy for myotomy and pneumatic dilation,
particularly with graded dilation (1-3 dilations with
progressively larger balloons)[56,57], as mentioned earlier,
myotomy has been shown to be a more effective
treatment for achalasia in several trials[37,38]. However,
pneumatic dilation is less expensive than myotomy and
still improves symptoms in a substantial number of 
patients[58-60]. In a meta-analysis of uncontrolled studies,
a single pneumatic dilation was found to be effective in
72% of patients during a mean follow-up of 4.9 years[61].
In a study of 150 patients with achalasia, pneumatic
dilations were performed until remission was achieved
or symptoms recurred, using an “on-demand strategy”
based on symptom recurrence, and a long-term remission
was achieved in nearly all patients[60]. Pneumatic dilation
can also be applied for some patients in whom dysphagia
persists after surgery[62,63]. In a study of 27 patients
with recurrent dysphagia following surgery, pneumatic
dilation improved symptoms in 76% of the patients[63].
If pneumatic dilation fails, laparoscopic myotomy with
fundoplication can be performed; the outcome is not
affected by previous pneumatic dilation[50,64]. 
A number of different balloon dilators have been used
over the years. A systematic review of the treatment of 
achalasia compared the results of using different dilators;
pneumatic dilation was performed in 2418 patients with
“old” dilators, in 234 patients with the “new” Witzel
dilator, and in 359 patients with the Rigiflex dilator[65].
Using old dilators and Witzel dilators, two-thirds of 
patients had good to excellent improvement after one or
more dilations during a mean follow-up of 4.6 years and
one year, respectively. Using Rigiflex dilators, an equivalent
improvement was achieved in up to 90% of patients,
depending upon the diameter of the dilator used (74%
for 3.0 cm, 86% for 3.5 cm, and 90% for 4.0 cm)[65]. At
present, the most popular pneumatic dilator is the Rigiflex
balloon, which is passed over a guidewire and positioned
www.wjgnet.com 
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fluoroscopically or endoscopically in the LES. This
balloon is available in three different sizes (3.0, 3.5, and
4.0 cm). The thinnest balloon is typically used in the first
dilating session. The standard approach to balloon dilation
is one dilatation per session; further need for dilation is
based on the symptomatic response. Patients are usually
referred to a surgeon if three consecutive dilations over
a few months do not provide clinical remission. In long-
term follow-ups, more than three sessions can be applied
if symptoms recur.
In our center we perform all dilations with the Rigiflex
balloon dilator. After a clear liquid diet for 24 h and an
overnight fast, patients receive intravenous diazepam
(5-10 mg) and meperidine (25-50 mg). A guidewire into
the stomach is placed under endoscopic visualization.
In the first dilating session, a 3.0 cm balloon dilator is
passed over the guidewire under endoscopic guidance.
The midpoint of the balloon is positioned at the LES.
The balloon is gradually inflated to 6 pounds per square
inch (psi) over 20 s and then to 8 psi for the next 20 s and
finally to 10 psi for 60 s. Then the balloon is deflated and
removed along with the guidewire. Patients are discharged
after a 6-h observation period. If severe or sustained chest
pain occurs, a gastrografin swallow is performed to rule
out perforation.
Using the above method we conducted a study of 99 
patients to assess therapeutic outcome after pneumatic 
dilation. Initially, all symptomatic patients underwent 
pneumatic dilation with a 3.0 cm balloon. If symptoms 
recurred, dilation was repeated with a 3.5 cm balloon. In 
the case of further relapse, a third dilation was carried 
out with a 4 cm balloon. The patients were followed for 
an average length of 47 (range, 18 to 60) mo. Dilation 
was repeated in 35 patients; only 6 of them required a
third dilation. After the third dilation two patients did 
not display improvement and underwent myotomy. Over 
the study period, cumulative remission rate was 65% 
without re-dilation and 94% with re-dilation. The mean 
remission period was 44.7 mo[66]. 
To address the optimal method for performing
pneumatic dilation, regarding the amount and rate of 
inflation pressure and balloon diameter, we conducted
a large long-term prospective study and enrolled 262
achalasia patients over 10 years. In the first 62 patients
(group A), dilation was done using a 3.5 cm balloon,
which was inflated to the pressure of 10 psi over 10 s.
In group B (200 patients), we initially used a 3.0 cm
balloon with inflation pressure of 10 psi in 30 s. We used
a Rigiflex balloon and maintained pressure for 60 s after
inflation in both groups. If symptoms recurred, dilation
was repeated with incrementally larger balloons (for
second dilation, 4.0 cm in group A and 3.5 cm in group B;
for third dilation, 4.0 cm in both groups). The cumulative
proportional remission rates with single dilation after 6
mo were 83% and 75% in groups A and B, respectively;
the corresponding rates decreased to 60% and 57%,
respectively, after 30 mo. The difference between the 2
methods was not statistically significant. The remission
rate following re-dilation was good; 1 year after the
second dilation, it was 88% in group A and 89% in group B,
and 2 years after the second dilation, it was 70% in both
groups. All perforations (n = 3) occurred in group A at the
first dilation (62 dilations) with rapid inflation of balloon
(10 psi over 10 s); while there was no perforation in group
B (296 dilations), in which gradual increasing of pressure
(10 psi over 30 s) and graded dilation method was used[67]. 
In another Iranian study, 45 patients who underwent 
pneumatic dilation were compared with 19 patients who 
underwent open myotomy. Good to excellent relief was 
achieved in 68% of patients with myotomy and 80% 
of patients with pneumatic dilation. After over 2 years 
of follow-up, relapse rates in both groups were not 
significantly different (39% in surgery group and 25% in 
pneumatic dilation group). The mean length of hospital 
stay and days off from work were significantly lower in 
the pneumatic dilation group; these were discovered to 
be 9 and 39 d in the myotomy group and 1 and 2 d in 
the pneumatic dilation group, respectively[57]. 
Some predictors for the outcome of pneumatic 
di lat ion have been sug gested, including age of 
patients[68,69] and a decrease in LES pressure following 
dilation[69]. In a study of 111 patients, short- and long-
term remission rates were good (98% and 75% at 
months 24 and 60, respectively), but young age (≤ 37.5 
years), high esophageal body pressure, and high LES 
pressure (≥ 17.5 mmHg) following first dilation were 
negative predictive factors. Young patients who required 
more than 2 dilations seemed not to benefit from this 
kind of treatment[70]. We did not find any significant 
association between age, gender, previous treatment, 
or severity of initial symptoms and the outcome of 
pneumatic dilation (P > 0.4)[66]. 
Esophageal perforation is the most important compli-
cation of pneumatic dilation. It occurs in approximately
3% to 5% of patients in most series, although the range
varies from 0% to 21%[3,71]. Patients with esophageal
perforation usually present in the first hours after dilation.
A high index of suspicion should be maintained in
patients complaining of sustained pain or discomfort after
the procedure. Some patients respond to conservative
treatment with antibiotics and parenteral nutrition but
others need a surgical repair. Other complications of 
pneumatic dilation include development of intramural
hematomas, esophageal mucosal tears, and diverticula at
the gastric cardia[72]. Severe transient and intermittent post-
procedural chest pain has been reported in approximately
15% of patients during the 24-48 h after dilation[73,74].
Although this symptom is disturbing, it is not harmful.
Botulinum toxin injection 
Botulinum toxin is a potent inhibitor of acetylcholine
release from nerve endings. The toxin theoretically relaxes
the LES by decreasing unopposed cholinergic stimulation
of the LES[75]. Although the effect of botulinum toxin
injection generally is shorter than some other procedures,
it can be useful under certain conditions. In patients with
multiple medical problems who are poor candidates for
more invasive procedures, as well as those unwilling to
undergo either surgery or pneumatic dilation, botulinum
toxin injection is the preferred approach. Older patients
www.wjgnet.com 
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and those who suffer from vigorous achalasia may benefit
more from botulinum toxin[76]. A multicenter randomized
study suggested that dose of botulinum toxin may be a
predictor of outcome: the higher the dose, the better the
[77]response . 
The use of botulinum toxin in achalasia was first 
introduced by Pasricha et al[78]. Several studies indicate 
that 65% to 90% of patients respond to a single injection 
within 1 mo. The effect of botulinum toxin lasts from
3 mo to more than one year[79-82]. Those who respond 
to the injection may do equally well after a second 
or even a third injection. In one series, for example, 
symptom relief was achieved in 75% of 57 patients 
who received repeated injections, as needed, during up 
to 2 years follow-up[31]. However, the effect decreases 
over time; some studies reported clinical remission 
rates of 50% and 30% at 6 and 12 mo, respectively, 
following botulinum injection[83]. Although a few studies 
reported that botulinum toxin injection could provide 
an efficacy equal to that of pneumatic dilation over a 
one year period[84], several randomized clinical trials have 
shown that while initial symptomatic remission rates 
by pneumatic dilation and botulinum injection may be 
similar in some cases, pneumatic dilation is associated 
with a significantly higher long-term remission rate[85,86]. 
In some studies, only pneumatic dilation was associated 
with improvement in objective measures of esophageal 
function, including esophageal manometry and barium 
studies[85,87]. In our trial of 40 patients, pneumatic dilation 
was more efficient than botulinum injection in providing 
sustained symptomatic relief over a 12 mo period. The 
remission rates for pneumatic dilation and botulinum 
injection after 12 mo were 52% and 15%, respectively[88]. 
Several formulations of botulinum toxin are available.
A comparison between 100 U of Botox and 250 U of 
Dysport showed a similar efficacy for up to 6 mo of 
follow-up[89]. In the most common method for injection
therapy, 1 mL aliquots (20 to 25 units/mL) of the toxin are
injected into each of four quadrants, approximately 1 cm
above the Z line, using a standard sclerotherapy needle.
We use and recommend the following method. After
an overnight fast, patients are sedated with intravenous
diazepam (5-10 mg) and meperidine (25-50 mg). The LES
is identified by visualization of the sphincter rosette at the
squamo-columnar junction during upper gastrointestinal
endoscopy. Four hundred units of Dysport are diluted
in 4 mL normal saline. Two 50-unit aliquots (0.5 mL) of 
Dysport are injected through a 5 mm sclerotherapy needle
into each quadrant of the LES. Patients are discharged
when routine post-sedation care is completed and allowed
to eat later on the same day. Improvement in symptoms is
usually observed after only 24 h; peak effects occur even
later in some patients. 
Reported complications after botulinum toxin are
not major and include post-procedural transient chest
pain (25%) and heartburn (5%)[90]. Transient chest
pain, the main complication, can be controlled by
sedatives. Neutralizing antibodies have been detected in
approximately 5% of patients treated chronically with
botulinum toxin for skeletal muscle conditions; however,
their significance in relapse of dysphagia in achalasia
is uncertain. These antibodies, however, might be a
possible cause of the rapid relapse of dysphagia following
botulinum toxin injection[91]. Surgical treatment of achalasia
in patients who previously received botulinum toxin may
encounter some technical problems, but no significant
difference in the outcome between patients with and
without previous use of the toxin has been reported[92].
Pneumatic dilation after botulinum toxin injection 
Only a few studies have investigated the effect of 
botulinum toxin injection on the outcome of pneumatic 
dilation. In a retrospective study of the effect of the 
combined therapy, we studied 12 patients who underwent 
dilation following botulinum toxin injection and 12 
patients with achalasia who underwent only pneumatic 
dilation (control group). With combined therapy, only 
one of the patients relapsed 30 mo after dilation, while all 
the others were in remission for an average of 25.6 mo.
In the control group, all the patients relapsed after a 
mean period of 12.6 mo and needed further dilation. 
The cumulative remission rate was significantly higher in 
the combined therapy group than in the control group
(P < 0.01). One month after dilation, the mean symptom 
score decreased by 76% in the combined therapy group 
and by 53% in the control group. Age, sex, duration and 
severity of symptoms were not correlated with response 
to treatment[93]. 
We also conducted a prospective trial. Twenty seven 
patients were randomly assigned to receive botulinum 
toxin 1 mo before pneumatic dilation and 27 patients 
were assigned to undergo pneumatic dilation alone. One-
year remission rates of patients in the botulinum toxin-
pneumatic dilation group and the pneumatic dilation 
group were 77% and 62%, respectively (P = 0.1). In 
the pneumatic dilation group, the esophageal barium 
height significantly decreased at 1 mo (P < 0.001), but 
this reduction did not persist over 1-year follow-up. 
The botulinum toxin-pneumatic dilation group showed 
a significant reduction in barium height at both 1 mo 
and 1 year after treatment (P < 0.001). In the botulinum 
toxin-pneumatic dilation group, 91% of patients older 
than 40 years were in remission at 1 year, compared with 
only 55% of this age group in the pneumatic dilation 
group (P = 0.07)[94]. 
We found an abstract in English that reported a
series of 9 patients with achalasia who were treated with
application of 250 IU Dysport into the LES and balloon
dilation 7 d later. Two patients underwent myotomy
because of poor relief of symptoms. Seven other patients,
however, were in good symptomatic remission after one
year. The remission was even observed for as long as
36 mo, which was the longest follow-up period[95]. 
Insertion of stents 
Only a few studies have investigated the role of 
expandable stents in treatment of achalasia[96-99]. The 
results are controversial. Therefore, insertion of stents 
does not seem to be a currently recommended treatment 
for achalasia. 
www.wjgnet.com 
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CONCLUSION
 
First stages of achalasia may be misdiagnosed as 
other diseases, such as GERD. Myotomy, particularly 
laparoscopic myotomy with fundoplication, is the 
most effective treatment for achalasia and can be 
considered as the procedure of choice. Compared to 
other treatments, however, the initial cost of myotomy 
is usually higher and the recovery period, particularly 
following open myotomy, is generally longer. When 
performing myotomy is not possible for any reason, 
e.g. medical contraindication, patient’s unwillingness, 
when patients cannot afford surgery, or experienced 
centers for surgery or post-operative care are not easily 
accessible (situations that may not be rare particularly 
in some low- or medium-resource countries), graded 
pneumatic dilation (using 3.0 cm balloons initially) with 
slow rate of balloon inflation seems to be an effective 
and safe initial alternative. The duration of remission 
can be extended by repeated dilation with larger-sized 
balloons. Injection of botulinum toxin into the LES 
before pneumatic dilation seems to increase remission 
rates. However, this needs to be confirmed in further 
studies. The timed esophagogram may be used as a non-
invasive objective tool for initial and post-operative or 
post-dilation assessment. 
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